Insider Selling: ICU Medical (NASDAQ:ICUI) Director Sells $304,300.00 in Stock

Key Points

• ICU Medical director Elisha Finney sold 1,700 shares for $304,300 at an average price of $179, leaving them with 4,871 shares—a 25.87% reduction in their position.
• The company beat quarterly earnings expectations, reporting EPS of $2.44 versus $2.14 expected and revenue of $556.22 million, up 4.4% year over year.
• Analysts have a consensus “Moderate Buy” rating and a $195.20 average price target; shares traded at $178.90 on Friday.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) Director Elisha Finney sold 1,700 shares of the stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $179.00, for a total value of $304,300.00. Following the sale, the director owned 4,871 shares of the company's stock, valued at $871,909. This represents a 25.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ICU Medical Price Performance

ICUI traded up $1.60 on Friday, hitting $178.90. 195,454 shares of the company's stock traded hands, compared to its average volume of 283,069. The company's 50 day simple moving average is $163.46 and its 200-day simple moving average is $149.76. The firm has a market cap of $4.47 billion, a price-to-earnings ratio of 74.85, a P/E/G ratio of 2.24 and a beta of 0.88. ICU Medical, Inc. has a one year low of $113.37 and a one year high of $192.85. The company has a current ratio of 2.37, a quick ratio of 1.19 and a debt-to-equity ratio of 0.52.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.30. ICU Medical had a net margin of 2.76% and a return on equity of 8.40%. The firm had revenue of $556.22 million for the quarter, compared to analysts' expectations of $552.03 million. During the same quarter last year, the business posted $2.03 earnings per share. The company's revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, research analysts anticipate that ICU Medical, Inc. will post 7.22 EPS for the current year.

Analysts Set New Price Targets

ICUI has been the topic of a number of recent research reports. Raymond James Financial reaffirmed a "strong-buy" rating and set a $200.00 price target on shares of ICU Medical in a research note on Friday, August 7th. Zacks Research downgraded shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Needham & Company LLC upped their target price on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research report on Friday, August 7th. KeyCorp increased their price target on shares of ICU Medical from $187.00 to $189.00 and gave the company an "overweight" rating in a report on Friday, November 6th. Finally, Weiss Ratings upgraded ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $195.20.

Institutional Trading of ICU Medical

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of ICU Medical in the 2nd quarter worth about $550,250,000. Jupiter Topco LLC purchased a new stake in ICU Medical in the 2nd quarter worth about $407,786,000. Janus Henderson Group PLC lifted its stake in ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier's stock worth $345,607,000 after purchasing an additional 99,256 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of ICU Medical by 6.8% during the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier's stock valued at $127,053,000 after buying an additional 63,026 shares during the period. Finally, Bank of America Corp DE purchased a new position in shares of ICU Medical during the second quarter valued at approximately $54,059,000. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.